Business
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. “We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica.
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.","length":322,"tagName":"p"},{"type":"text","content":"“We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “As a highly accomplished drug development executive and physician, Noah’s deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of molluscum contagiosum and advance our clinical-stage programs in basal cell carcinoma and common warts. Dr. Rosenberg brings to Verrica more than 30 years of clinical and therapeutic development experience with multiple global drug approvals across a number of therapeutic areas, including dermatology.”","length":688,"tagName":"p"},{"type":"text","content":"“I would also like to thank Gary Goldenberg for his many contributions to Verrica over the last several years, which included the U.S. Food and Drug Administration’s approval of YCANTH for the treatment of molluscum contagiosum. He stepped into the role of CMO from our Board of Directors when Verrica needed him most and has guided Verrica’s development programs while providing clinical care to dermatology patients and being an advocate for patients and clinicians at the podium of many medical and scientific conferences. We are grateful to still have Gary’s expertise as part of the Verrica team as a strategic advisor and consultant while he spends more time caring for his patients...